Patients with a combination of left ventricular dysfunction and low aortic valve gradient have higher mortality rates and a greater risk of recurrent heart failure after transcatheter aortic valve replacement (TAVR).

Direct Flow Medical Inc. presented three-year results from its prospective, multicenter DISCOVER Trial at the EuroPCR meeting in Paris.

Using optimal frequency domain imaging (OFDI) to guide percutaneous coronary intervention (PCI) with second-generation drug eluting stents (DES) achieves equivalent clinical and angiographic outcomes to intravascular ultrasound (IVUS)-guided PCI at 12 months.


Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater risk of stroke. These strokes resulting from the embolization of left atrial appendage (LAA) thrombi account for up to 25 percent of the 700,000 cerebrovascular strokes annually in the United States.[1] Many experts believe the LAA is the culprit in a much higher percentage of strokes.


Physician-researchers in the College of Medicine at the University of Cincinnati have developed a computerized decision support tool to assist physicians and patients with decisions about blood thinning treatment to prevent strokes in individuals with atrial fibrillation.

BioVentrix announced the first-in-man use of its next-generation Revivent-TC System with an endovascular catheter-based approach from within the left ventricle.

St. Jude Medical Inc. announced results from two cardiovascular clinical trials presented at EuroPCR 2016.


There were many opinions on the duration of dual antiplatelet therapy (DAPT) highlighted at the 2016 American College of Cardiology (ACC.16) meeting. A general theme was DAPT prolongation and patient stratification, which was relevant to the recent release of the ACC and the American Heart Association’s (AHA) 2016 Focused Update in Duration of DAPT in Patients with Coronary Artery Disease (CAD). Although sessions at ACC.16 helped clarify the recent guidelines, questions still remain.


Bioabsorbable heart valves or blood vessels are designed to harness the body’s innate healing process, enabling the natural restoration of complex body parts as the synthetic graft is absorbed.

The TRANSFORM trial was designed to evaluate the safety and performance of an investigational rapid deployment aortic valve replacement (RDAVR) system for patients with severe aortic stenosis.

Subscribe Now